Patents by Inventor Barry J. Simon

Barry J. Simon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tumoricidal and antimicrobial composition
    Patent number: 10772912
    Abstract: Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of NK-92 cell medium and methods of using the compositions for killing cancer cells.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: September 15, 2020
    Assignee: NantKwest, Inc.
    Inventors: Hans G. Klingemann, Barry J. Simon
  • Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer
    Patent number: 10736921
    Abstract: This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: August 11, 2020
    Assignee: NantKwest, Inc.
    Inventors: Tien Lee, Hans G. Klingemann, Barry J. Simon, Laurent Boissel
  • Tumoricidal and antimicrobial compositions and methods
    Patent number: 10646516
    Abstract: Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of NK-92 cell medium and methods of using the compositions for killing cancer cells.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: May 12, 2020
    Assignee: NantKwest, Inc.
    Inventors: Hans G. Klingemann, Barry J. Simon
  • TUMORICIDAL AND ANTIMICROBIAL COMPOSITIONS AND METHODS
    Publication number: 20200038445
    Abstract: Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of NK-92 cell medium and methods of using the compositions for killing cancer cells.
    Type: Application
    Filed: October 10, 2019
    Publication date: February 6, 2020
    Inventors: Hans G. Klingemann, Barry J. Simon
  • Tumoricidal and antimicrobial compositions and methods
    Patent number: 10517895
    Abstract: Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of NK-92 cell medium and methods of using the compositions for killing cancer cells.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: December 31, 2019
    Assignee: NANTKWEST, INC.
    Inventors: Hans G. Klingemann, Barry J. Simon
  • GENETICALLY MODIFIED NK-92 CELLS AND MONOCLONAL ANTIBOIDES FOR THE TREATMENT OF CANCER
    Publication number: 20190365816
    Abstract: This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor.
    Type: Application
    Filed: August 15, 2019
    Publication date: December 5, 2019
    Inventors: Tien Lee, Hans G. Klingemann, Barry J. Simon, Laurent Boissel
  • Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer
    Patent number: 10456420
    Abstract: This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: October 29, 2019
    Assignee: NantKwest, Inc.
    Inventors: Tien Lee, Hans G. Klingemann, Barry J. Simon, Laurent Boissel
  • TUMORICIDAL AND ANTIMICROBIAL COMPOSITIONS AND METHODS
    Publication number: 20190192570
    Abstract: Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of NK-92 cell medium and methods of using the compositions for killing cancer cells.
    Type: Application
    Filed: February 28, 2019
    Publication date: June 27, 2019
    Applicant: NantKwest, Inc.
    Inventors: Hans G. Klingemann, Barry J. Simon
  • TUMORICIDAL AND ANTIMICROBIAL COMPOSITIONS AND METHODS
    Publication number: 20190192568
    Abstract: Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of NK-92 cell medium and methods of using the compositions for killing cancer cells.
    Type: Application
    Filed: February 28, 2019
    Publication date: June 27, 2019
    Applicant: NantKwest, Inc.
    Inventors: Hans G. Klingemann, Barry J. Simon
  • TUMORICIDAL AND ANTIMICROBIAL COMPOSITIONS AND METHODS
    Publication number: 20190192569
    Abstract: Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of NK-92 cell medium and methods of using the compositions for killing cancer cells.
    Type: Application
    Filed: February 28, 2019
    Publication date: June 27, 2019
    Applicant: NantKwest, Inc.
    Inventors: Hans G. Klingemann, Barry J. Simon
  • TUMORICIDAL AND ANTIMICROBIAL COMPOSITIONS AND METHODS
    Publication number: 20190125801
    Abstract: Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of NK-92 cell medium and methods of using the compositions for killing cancer cells.
    Type: Application
    Filed: December 6, 2018
    Publication date: May 2, 2019
    Applicant: NantKwest, Inc.
    Inventors: Hans G. Klingemann, Barry J. Simon
  • Tumoricidal and antimicrobial compositions and methods
    Patent number: 10258649
    Abstract: Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of NK-92 cell medium and methods of using the compositions for killing cancer cells.
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: April 16, 2019
    Assignee: NANTKWEST, INC.
    Inventors: Hans G. Klingemann, Barry J. Simon
  • GENETICALLY MODIFIED NK-92 CELLS AND MONOCLONAL ANTIBODIES FOR THE TREATMENT OF CANCER
    Publication number: 20180193383
    Abstract: This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor.
    Type: Application
    Filed: March 25, 2016
    Publication date: July 12, 2018
    Applicant: NantKwest, Inc.
    Inventors: Tien Lee, Hans G. Klingemann, Barry J. Simon, Laurent Boissel
  • NK-92 CELLS IN COMBINATION THERAPY WITH CANCER DRUGS
    Publication number: 20170304364
    Abstract: This disclosure is directed to compositions and methods for treating cancer using combination therapies of NK-92 cells with cancer drugs (e.g. thalidomide, cisplatin, and paclitaxel).
    Type: Application
    Filed: March 25, 2016
    Publication date: October 26, 2017
    Applicant: NantKwest, Inc.
    Inventors: Tien Lee, Hans G. Klingemann, Barry J. Simon
  • TUMORICIDAL AND ANTIMICROBIAL COMPOSITIONS AND METHODS
    Publication number: 20160250256
    Abstract: Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of NK-92 cell medium and methods of using the compositions for killing cancer cells.
    Type: Application
    Filed: October 28, 2014
    Publication date: September 1, 2016
    Applicant: NantKwest, Inc.
    Inventors: Hans G. Klingemann, Barry J. Simon
  • PROTOCOL AND MEDIA FOR STORAGE AND TRANSPORT OF NK-92 CELL LINE
    Publication number: 20160244716
    Abstract: Described herein is a storage medium for transport of NK-92 cells comprising human serum, about 200 IU/mL and a density of non-irradiated NK-92 cells sufficient to provide a therapeutic amount of NK-92 cells at the time of delivery to a treatment facility, wherein the temperature of the medium is maintained within +/?5° C. of a selected temperature between 20° C. and 40° C., such that the NK-92 cells remain viable for administration to a patient for up to a period of at least 24 hours after placement into the storage medium. Also described are methods of transporting NK-92 cells such that the NK-92 cells remain viable for administration to a patient for up to a period of at least 24 hours after placement into the storage medium.
    Type: Application
    Filed: October 7, 2014
    Publication date: August 25, 2016
    Inventors: Hans G. Klingemann, Barry J. Simon